Articles tagged "Induction therapy"

2020 American Transplant Congress
Short Term Outcomes in Kidney Transplant Patients Receiving De Novo Belatacept with Anti-Thymocyte Globulin Induction
B. Carlson, P. Cabrera, T. Harrison, K. Tejani, A. Centeno
Pharmacy, Jackson Memorial Hospital, Miami, FL
*Purpose: Mainstay immunosuppressive therapy after kidney transplant is a calcineurin inhibitor (CNI) based regimen. Nephrotoxicity is a common adverse effect of CNIs which can lead…
2020 American Transplant Congress
Peri-Operative Extracorporeal Photopheresis in High Risk Patients after Heart Transplantation
A. Zuckermann¹, J. Gökler¹, N. Worel², P. Angleitner¹, E. Ceran¹, E. Ceran¹, N. Neuber¹, P. Kaiser¹, G. Laufer¹, A. Aliabadi-Zuckermann¹
¹Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, ²Department of Transfusion Medicine, Medical University of Vienna, Vienna, Austria
*Purpose: Extracorporeal photopheresis (ECP) is an established therapy for treatment of heart transplant rejection and is also applied for rejection prevention in the perioperative setting…
2020 American Transplant Congress
Anti-HLA IgM Antibodies are Unaffected by Imlifidase (IdeS) Treatment
A. Runström¹, R. Bockermann¹, K. Sjöholm¹, K. M. Roupé¹, Å. Schiött¹, L. Winstedt¹, C. Kjellman¹, T. Lorant²
¹Hansa Biopharma AB, Lund, Sweden, ²Section of Transplantation Surgery, Department of Surgical Sciences, Uppsala, Sweden
*Purpose: The immunoglobulin G (IgG)-degrading cysteine protease, imlifidase (IdeS) is an IgG endopeptidase under development as a rapid desensitization treatment in kidney transplantation. Imlifidase is…
2020 American Transplant Congress
Outcomes of Induction with T Lymphocyte-Depleting and IL-2 Receptor Blocking (IL-2RB) Antibodies in the Non-Broadly Sensitized Adult Deceased-Donor Kidney Transplant Recipients: Analysis in the Context of the CPRA Allocation System
A. H. Santos Jr¹, Y. Li², K. Alquadan¹, M. Leghrouz¹, X. Wen³
¹Div. of Nephrology, Univ. of Florida, Gainesville, FL, ²Univ. of Florida, Gainesville, FL, ³Univ. of Rhode Island, Kingston, RI
*Purpose: We studied outcomes of induction in non-broadly-sensitized adult deceased-donor kidney transplant recipients(DD-KTRs) in the context of the calculated panel reactive antibody (CPRA) allocation system.*Methods:…
2020 American Transplant Congress
Comparison of Short-Term Outcomes of Induction Therapy with Alemtuzumab versus Rabbit Antithymocyte Globulin in Lung Transplantation
V. Liu, M. W. Soto-Arenall, A. Patel
Pharmacy, Mayo Clinic, Jacksonville, FL
*Purpose: To identify the short-term efficacy and safety outcomes of alemtuzumab (C1H) versus rabbit antithymocyte globulin (rATG) in lung transplant patients. The objectives are to…
2020 American Transplant Congress
Induction Immunosuppression in Primary Pediatric Liver Transplant Recipients
T. Shaker¹, K. Ramanathan¹, S. Riad², D. Vock³, S. Chinnakotla¹
¹Surgery, Division of Transplantation, University of Minnesota, Minneapolis, MN, ²Division of Renal Diseases and Hypertension, University of Minnesota, Minneapolis, MN, ³Biostatistics, University of Minnesota, Minneapolis, MN
*Purpose: Induction immunosuppression for pediatric liver transplants varies widely among centers. We sought to evaluate the impact of different induction regimens on patient and graft…
2020 American Transplant Congress
Outcomes of Intra-Operative Steroid Induction in Liver Transplant Recipients
A. Poparad-Stezar, A. Jantz, T. Larson, B. Summers, N. Sulejmani
Henry Ford Hospital, Detroit, MI
*Purpose: Evidence supporting the use of antibody induction (AI) immunosuppression (IS) (antithymocyteglobulin (rATG) and basiliximab (BAS)) for acute rejection (AR) prophylaxis in liver transplant is…
2020 American Transplant Congress
Depletional Profiles of Human and Rhesus Specific Anti-Thymocyte Globulins in Rhesus Macaques
B. I. Shaw¹, R. Schmitz¹, D. M. Magnani², F. Leopardi¹, A. D. Kirk¹
¹Surgery, Duke University, Durham, NC, ²Medicine, MassBiologics of the University of Massachusetts Medical School, Boston, MA
*Purpose: Rabbit anti-human ATG (rATG; Thymoglobulin®) is the most commonly used formulation for depletional induction therapy in the United States. However, given that it is…
2019 American Transplant Congress
Impact of Induction Choice and Early Steroid Withdrawal on Outcomes in HLA Zero Mismatched Kidney Transplant Recipients
C. Votruba¹, K. Holdener¹, B. Astor², F. Aziz², D. Mandelbrot²
¹Pharmacy, University of Wisconsin Hospitals and Clinics, Madison, WI, ²Nephrology, University of Wisconsin Hospitals and Clinics, Madison, WI
*Purpose: Ideal induction and immunosuppression therapy for 6-antigen HLA matched deceased and living kidney transplant recipients (KTR) is not well understood.*Methods: All 6-antigen HLA matched…
2019 American Transplant Congress
Low Dose Anti-Thymocyte Globulin is Enough to Prevent Acute Cellular Rejection in Kidney Transplant
P. W. Baron¹, J. Weissman², F. Fazeli³, C. Zuppan⁴, R. Villicana³, P. Wai¹, L. Beeson⁵, M. De Vera¹
¹Surgery/Transplantation Institute, Loma Linda University Health, Loma Linda, CA, ²Pharmacy, Loma Linda University Health, Loma Linda, CA, ³Transplantation Institute, Loma Linda University Health, Loma Linda, CA, ⁴Pathology, Loma Linda University Health, Loma Linda, CA, ⁵Center for Nutrition, Healthy Lifestyle and Disease Prevention/School of Public Health, Loma Linda University Health, Loma Linda, CA
*Purpose: Rabbit anti-thymocyte globulin (rATG) cumulative dose needed to effectively and safely prevent acute cellular rejection is unknown. This study compares the efficacy of total…

« Previous Page
1
…
7
8
9
10
11
…
31
Next Page »